Frontierby eninvs

Language: EN · RU

← Region

Kalbe Farma (KLBF) USD

Kalbe Farma develops, manufactures, and sells pharmaceutical products, including prescription drugs, consumer health items, and nutritional products, and also operates distribution and logistics services in Indonesia.

At a glance: strengths & risks
✓Revenue growing (+8%)✓Profit growing (+112995%)✓Margins improving (0%→15%)✓Net cash balance sheet

Sector: Pharmaceuticals

ID_KLBF

Price chart

735 IDRDay -2.65%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
735 IDR · -2.65%
Market cap
1.9 bn USD

Growth

Δ revenue y/y
4.2%
Δ EBITDA y/y
—

Multiples

P/E (LTM)
5.6x
P/B (FY)
1.3x
EV/EBITDA (LTM)
3.8x

Cash return

Dividend yield
2.7%
FCF yield (LTM)
-0.0%

Liquidity

Daily turnover (listing)
79.6 bln IDR

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueM USDOperating profitM USDD&AM USDEBITDAM USDNet profitM USDOperating CFM USDCapex + M&AM USDAssetsM USDEquityM USDROE (annualized)Net debtM USDSource
2026-06-30Q2 2026 (3M)OK0.6
y/y —
0.1
y/y —
0.0
y/y —
0.1
y/y —
0.0
y/y —
0.10.01.9
y/y —
1.4
y/y —
15.5%-0.2Report (PDF)
2026-03-31Q1 2026 (3M)OK0.6
y/y —
0.1
y/y —
0.0
y/y —
0.1
y/y —
0.1
y/y —
0.00.01.9
y/y —
1.5
y/y —
16.7%-0.2Report (PDF)
2025-12-31Q4 2025 (3M)OK0.6
y/y —
0.1
y/y —
0.0
y/y —
0.1
y/y —
0.1
y/y —
0.10.01.8
y/y 1.0%
1.5
y/y —
15.6%-0.2Report (PDF)
2025-09-30Q3 2025 (3M)OK1.6
y/y —
0.2
y/y —
0.0
y/y —
0.2
y/y —
0.2
y/y —
0.10.01.8
y/y —
1.4
y/y —
31.1%-0.2Report (PDF)
2024-12-31FY 2024 (12M)OK2.1
y/y —
0.0
y/y —
0.0
y/y —
0.0
y/y —
0.0
y/y —
0.0-907.91.8
y/y —
0.0
y/y —
—0.0Report (PDF)

Net debt structure (leases included, IFRS 16) 2026-06-30

Short-term debt (incl. ST leases)0
Long-term debt (incl. LT leases)0
− Cash & equivalents0
Net debt-0

Revenue & EBITDA

RevenueEBITDA

Quarterly values ($ mln)

001222024 FY2025 9M2025 q42026 q12026 q2

Cash flow

FCF ($ mln)

0000002024 FY2025 9M2025 q42026 q12026 q2

Net debt / cash ($ mln)

-0-0-0-0-002024 FY2025 q32025 q42026 q12026 q2

Profit and cash

Profit is cash-backed
In a typical year of 2024–2025 operating cash flow came to 1.19x of reported net profit.
year20242025
cash flow / profit1.48x0.89x
accruals, % of assets-0.0%1.3%
Last twelve months (to 2026-06-30): 0.81x of profit came back as operating cash flow.
net debt / EBITDA -0.5x
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Research & reviews

Our earnings breakdowns and investment notes on this issuer.

All research →

Indonesia — currency context

USD/IDR17606
1-week-0.1%
1-month-1.4%
room to 52w-weakest3.3%
DXY (dollar index)99.1
US 10Y4.93%

A weaker rupiah lowers the USD value of Indonesian equities for a foreign holder; for banks, BI's high policy rate (defending the currency) pressures margins.

as of 2026-09-11 (Yahoo)

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-06-0420 IDREx-dividend: 20 IDR per sharePaidYahoo Finance (ex-div)
2025-06-0436 IDREx-dividend: 36 IDR per sharePaidYahoo Finance (ex-div)
2024-05-2931 IDREx-dividend: 31 IDR per sharePaidYahoo Finance (ex-div)
2023-05-1238 IDREx-dividend: 38 IDR per sharePaidYahoo Finance (ex-div)
2022-05-3135 IDREx-dividend: 35 IDR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Investor reporting (IR): https://www.kalbe.co.id/investor-relations

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Kalbe Farma (KLBF) — from primary filings.

Frequently asked questions

What is Kalbe Farma (KLBF)'s P/E ratio?
Kalbe Farma (KLBF) trades at a P/E of 5.6x (price to trailing 12-month earnings).
What is Kalbe Farma (KLBF)'s EV/EBITDA?
Kalbe Farma (KLBF) trades at 3.8x EV/EBITDA.
What is Kalbe Farma (KLBF)'s P/B ratio?
Kalbe Farma (KLBF) trades at a P/B of 1.3x.
What is Kalbe Farma (KLBF)'s dividend yield?
Kalbe Farma (KLBF)'s trailing 12-month dividend yield is 2.7%.
What is Kalbe Farma (KLBF)'s return on equity (ROE)?
Kalbe Farma (KLBF)'s ROE is 15.5%.
What is Kalbe Farma (KLBF)'s market capitalization?
Kalbe Farma (KLBF)'s market cap is 1.9 bn USD.

See also: Indonesian Stocks (2026): The Cheapest Big Emerging Market · The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map